glp-1 drugs for parkinson's disease Ozempic and other were initially understood as a metabolism breakthrough: medicines that act like hormones to control hunger, blood sugar and weight. But as researchers probe deeper into how the GLP-1 does not slow Parkinson's

CONFLICT OF INTEREST STATEMENT MB, CR and SF have no conflicts of interests to disclose

It is not a DEA-controlled substance as of 2025

The creation of individualized nutraceutical regimens based on a persons genetic composition, microbiome composition, lifestyle, and disease risk profile is one of the main directions

The medication should appear as specified in the dispensing instructionseither as a white to off-white lyophilized powder or, if pre-reconstituted, as a clear, colorless to slightly yellow solution

Current and emerging therapies act on key metabolic pathways: 1) hepatospecific activation of thyroid hormone receptor (THR) to increase -oxidation and reduce lipogenesis (resmetirom)